Skip to main content

Table 3 Regression analysis of the sub-group analysis (BMI ≥ 50) after PS matching

From: Evaluation of Apixaban safety and effectiveness in morbidly obese patients with atrial fibrillation: a retrospective cohort study

Outcomes

Number of outcomes/Total number of patients

P-value$

BMI < 40 (n = 24)

BMI ≥ 50 (n = 24)

Arterial/ Venous Thrombosis

 All thrombosis cases, n (%) ∆

0 (0)

0 (0)

NA

 Venous Thromboembolism (VTE), n(%)∆

0 (0)

0 (0)

NA

 Ischemic Stroke, n (%) ∆

0 (0)

0 (0)

NA

Bleeding

 Major Bleeding, n(%)∆

0 (0.0)

1 (4.2)

0.31**

 Minor Bleeding, n(%)∆

3 (12.5)

1 (4.2)

0.29**

  1. ∆ Denominator of the percentage is the total number of patients
  2. ** Fisher test is used to calculate the P-value
  3. $ Propensity score matched used based patient’s age, gender and HAS-BLED score